Creation of a long-acting nanoformulated dolutegravir

Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable apparent half-life and the potential for bimonthly...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brady Sillman, Aditya N. Bade, Prasanta K. Dash, Biju Bhargavan, Ted Kocher, Saumi Mathews, Hang Su, Georgette D. Kanmogne, Larisa Y. Poluektova, Santhi Gorantla, JoEllyn McMillan, Nagsen Gautam, Yazen Alnouti, Benson Edagwa, Howard E. Gendelman
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/9fe938444e464eaea1e85845549ff241
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9fe938444e464eaea1e85845549ff241
record_format	dspace
spelling	oai:doaj.org-article:9fe938444e464eaea1e85845549ff2412021-12-02T17:33:06ZCreation of a long-acting nanoformulated dolutegravir10.1038/s41467-018-02885-x2041-1723https://doaj.org/article/9fe938444e464eaea1e85845549ff2412018-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-02885-xhttps://doaj.org/toc/2041-1723Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable apparent half-life and the potential for bimonthly drug administration.Brady SillmanAditya N. BadePrasanta K. DashBiju BhargavanTed KocherSaumi MathewsHang SuGeorgette D. KanmogneLarisa Y. PoluektovaSanthi GorantlaJoEllyn McMillanNagsen GautamYazen AlnoutiBenson EdagwaHoward E. GendelmanNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Brady Sillman Aditya N. Bade Prasanta K. Dash Biju Bhargavan Ted Kocher Saumi Mathews Hang Su Georgette D. Kanmogne Larisa Y. Poluektova Santhi Gorantla JoEllyn McMillan Nagsen Gautam Yazen Alnouti Benson Edagwa Howard E. Gendelman Creation of a long-acting nanoformulated dolutegravir
description	Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable apparent half-life and the potential for bimonthly drug administration.
format	article
author	Brady Sillman Aditya N. Bade Prasanta K. Dash Biju Bhargavan Ted Kocher Saumi Mathews Hang Su Georgette D. Kanmogne Larisa Y. Poluektova Santhi Gorantla JoEllyn McMillan Nagsen Gautam Yazen Alnouti Benson Edagwa Howard E. Gendelman
author_facet	Brady Sillman Aditya N. Bade Prasanta K. Dash Biju Bhargavan Ted Kocher Saumi Mathews Hang Su Georgette D. Kanmogne Larisa Y. Poluektova Santhi Gorantla JoEllyn McMillan Nagsen Gautam Yazen Alnouti Benson Edagwa Howard E. Gendelman
author_sort	Brady Sillman
title	Creation of a long-acting nanoformulated dolutegravir
title_short	Creation of a long-acting nanoformulated dolutegravir
title_full	Creation of a long-acting nanoformulated dolutegravir
title_fullStr	Creation of a long-acting nanoformulated dolutegravir
title_full_unstemmed	Creation of a long-acting nanoformulated dolutegravir
title_sort	creation of a long-acting nanoformulated dolutegravir
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/9fe938444e464eaea1e85845549ff241
work_keys_str_mv	AT bradysillman creationofalongactingnanoformulateddolutegravir AT adityanbade creationofalongactingnanoformulateddolutegravir AT prasantakdash creationofalongactingnanoformulateddolutegravir AT bijubhargavan creationofalongactingnanoformulateddolutegravir AT tedkocher creationofalongactingnanoformulateddolutegravir AT saumimathews creationofalongactingnanoformulateddolutegravir AT hangsu creationofalongactingnanoformulateddolutegravir AT georgettedkanmogne creationofalongactingnanoformulateddolutegravir AT larisaypoluektova creationofalongactingnanoformulateddolutegravir AT santhigorantla creationofalongactingnanoformulateddolutegravir AT joellynmcmillan creationofalongactingnanoformulateddolutegravir AT nagsengautam creationofalongactingnanoformulateddolutegravir AT yazenalnouti creationofalongactingnanoformulateddolutegravir AT bensonedagwa creationofalongactingnanoformulateddolutegravir AT howardegendelman creationofalongactingnanoformulateddolutegravir
_version_	1718380078693351424

Creation of a long-acting nanoformulated dolutegravir

Ejemplares similares